Eton Pharma’s pipeline includes patented formulations of Corticotropin injection and Pentoxifylline injection, as well as numerous undisclosed injectable and ophthalmic products in late-stage development. All products in Eton Pharma’s pipeline will be filed with the FDA under the 505(b)(2) regulatory pathway, and Eton anticipates filing its first New Drug Application in 2018.
Anticipated NDA Filing Timeline
©2017 by Eton Pharmaceuticals
21925 W. Field Pkwy, Suite 235
Deer Park, IL 60010